Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

E-Therapeutics Granted Approval For Phase I Trials Of Anti-cancer Drug ETS2101

3/29/2012 2:48 AM ET

Biotechnology company e-Therapeutics Plc (ETX.L) Thursday announced that its plans for Phase-1 trials of its anti-cancer drug ETS2101 have received approvals from the regulatory authorities both in the UK and in the US.

Following the receipt of approvals, the company reaffirmed that enrolment of patients for the Phase-1 trial in both the US and the UK would be commencing shortly.

Professor Malcolm Young, CEO of e-Therapeutics, said: "We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year."

Click here to receive FREE breaking news email alerts for e-Therapeutics plc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Israel on Thursday announced it has suspended the US-mediated peace talks with the Palestinians in response to a unity accord reached between the two rival Palestinian groups, the Hamas and the Fatah. The development comes just a day after the Hamas, a radical Islamist group that controls Gaza, and the Fatah faction that rules the West Bank announced a reconciliation deal. The two groups said they While U.S. President Barack Obama and his Russian counterpart Vladimir Putin have called for a diplomatic solution to the ongoing crisis in Ukraine, the two leaders both made comments Thursday with the potential to inflame rather than tamp down the situation. After initially showing a lack of direction, stocks have moved mostly higher over the course of the trading day on Thursday. The strength that has emerged on the day has largely offset the weakness that was seen in the previous session. The major averages have moved roughly sideways in recent trading, hovering in positive territory.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.